Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer

Gastric Cancer, Version 2.2013

(2017) Jaffer A. Ajani et al.   Journal of the National Comprehensive Cancer Network

Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) T. Waddell et al.   ANNALS OF ONCOLOGY

Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population

(2013) Xiang-Shan Fan   WORLD JOURNAL OF GASTROENTEROLOGY

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

(2012) Y. Y. Janjigian et al.   ANNALS OF ONCOLOGY

HER2/neutesting for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

(2012) Carlos Gómez-Martin et al.   JOURNAL OF CLINICAL PATHOLOGY

HER2 testing in gastric cancer: a practical approach

(2012) Josef Rüschoff et al.   MODERN PATHOLOGY

Classification OMS 2010 des tumeurs digestives : la quatrième édition

(2011) Jean-François Fléjou   ANNALES DE PATHOLOGIE

Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens

(2011) Jiyuan Yang et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Japanese classification of gastric carcinoma: 3rd English edition

(2011)   Gastric Cancer

Dual-colour HER2/Chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples

(2011) B. Yan et al.   JOURNAL OF CLINICAL PATHOLOGY

HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population

(2011) Pamela L. Kunz et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE